Saltar al contenido
Merck

Caffeine intake and the risk of kidney stones.

The American journal of clinical nutrition (2014-11-21)
Pietro Manuel Ferraro, Eric N Taylor, Giovanni Gambaro, Gary C Curhan
RESUMEN

Although caffeine intake may increase urine calcium excretion, caffeine-containing beverages have been associated with a lower risk of nephrolithiasis. We sought to determine the association between caffeine intake and the risk of incident kidney stones in 3 large prospective cohorts. We prospectively analyzed the association between intake of caffeine and incidence of kidney stones in 3 large ongoing cohort studies, the Health Professionals Follow-Up Study (HPFS) and the Nurses' Health Studies (NHS) I and II. Information on the consumption of caffeine and the incidence of kidney stones was collected by validated questionnaires. The analysis included 217,883 participants; over a median follow-up of >8 y, 4982 incident cases occurred. After multivariate adjustment for age, BMI, fluid intake, and other factors, participants in the highest quintile of caffeine intake had a 26% (95% CI: 12%, 38%) lower risk of developing stones in the HPFS cohort, a 29% lower risk (95% CI: 15%, 41%) in the NHS I cohort, and a 31% lower risk (95% CI: 18%, 42%) in the NHS II cohort (P-trend < 0.001 for all cohorts). The association remained significant in the subgroup of participants with a low or no intake of caffeinated coffee in the HPFS cohort. Among 6033 participants with 24-h urine data, the intake of caffeine was associated with higher urine volume, calcium, and potassium and with lower urine oxalate and supersaturation for calcium oxalate and uric acid. Caffeine intake is independently associated with a lower risk of incident kidney stones.

MATERIALES
Número de producto
Marca
Descripción del producto

Supelco
Caffeine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Caffeine, powder, ReagentPlus®
Sigma-Aldrich
Ácido úrico, ≥99%, crystalline
Sigma-Aldrich
Caffeine, anhydrous, 99%, FCC, FG
USP
Caffeine, United States Pharmacopeia (USP) Reference Standard
Supelco
Schmelzpunktstandard 235-237°C, analytical standard
Supelco
Caffeine Melting Point Standard, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ácido úrico, BioXtra, ≥99% (HPLC)
Supelco
Caffeine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Caffeine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
USP
Caffeine melting point standard, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Caffeine, Sigma Reference Standard, vial of 250 mg
Sigma-Aldrich
Caffeine, meets USP testing specifications, anhydrous
Supelco
Caffeine solution, analytical standard, 1.0 mg/mL in methanol
Supelco
Mettler-Toledo Calibration substance ME 18872, Caffeine, traceable to primary standards (LGC)
Sigma-Aldrich
Caffeine, anhydrous, tested according to Ph. Eur.
Calcium oxalate monohydrate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Caffeine, BioXtra
Caffeine for system suitability, European Pharmacopoeia (EP) Reference Standard
Caffeine, European Pharmacopoeia (EP) Reference Standard